ELI LILLY & Co
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3025% above fair value
$1410.99−6.55 (-0.46%)
Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%
Eli Lilly Strattera (atomoxetine) by Year
Strattera (atomoxetine) — Worldwide revenue YoY (%) [legacy] (%)
Eli Lilly Strattera (atomoxetine): -27.0% in FY2019, up 1.0 pts from a year earlier. No newer figure appears in the documents we track.
Latest, FY2019
-27.0%
Period ended Dec 31, 2019
Change on a year earlier
+1.0 pts
-28.0% in FY2018
History
3 years
Since FY2017
Sources
3
Documents cited below
Where the FY2019 figure comes from
“|| Strattera | 89.7 | 361.1 | 450.8 | 618.2 | (27 | )”
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Strattera (atomoxetine) — Worldwide revenue YoY (%) [legacy] (%) | Year on year | Source |
|---|---|---|---|---|
| FY2019 | Dec 31, 2019 | -27.0% | +1.0 pts | Form 10-K FY2019 (filed 2020-02-19) ↗ |
| FY2018 | Dec 31, 2018 | -28.0% | -37.0 pts | Form 10-K FY2018 (filed 2019-02-19) ↗ |
| FY2017 | Dec 31, 2017 | 9.0% | – | Form 10-K FY2017 (filed 2018-02-20) ↗ |
Cite this data
StockData. (2026). Eli Lilly Strattera (atomoxetine) (%), annual FY2017–FY2019 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med-strattera-yoy
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.